{
    "clinical_study": {
        "@rank": "166618", 
        "arm_group": {
            "arm_group_label": "14C labeled ASP3652", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study measures how much of the trial drug enters the body and how long it takes for the\n      body to remove it via the feces and urine. In addition, the different breakdown products\n      after a single oral dose of radio-active ASP3652 will be identified."
        }, 
        "brief_title": "A Study to Assess the Pharmacokinetics, Metabolism and Excretion Routes of ASP3652 in Man, After Administration of 14C Radio Labeled ASP3652", 
        "completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Healthy Subjects", 
            "Pharmacokinetics of ASP3652"
        ], 
        "detailed_description": {
            "textblock": "This is an open-label, one-period, single-dose study with 14C labeled ASP3652.\n\n      Screening takes place between Day  22 to Day  2, and subjects are admitted to the clinic on\n      Day -1.\n\n      On the morning of Day 1, each subject receives a single oral dose of 14C-labeled ASP3652.\n      Blood, urine and feces samples for analysis of 14C radioactivity are collected until at\n      least 120 h after dosing. Blood samples for the analysis of ASP3652 and metabolites are\n      collected until 120 h after dosing.\n\n      The subjects remain in the clinic until Day 6 (or up to Day 13 in case discharge criteria\n      are not met on Day 6) and return for an End of Study Visit (ESV) 7 to 14 days after (early)\n      discharge."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is white and of Caucasian origin.\n\n          -  Regular defecation pattern (minimum once per day).\n\n          -  Subject must agree to use a condom during sexual intercourse until 3 months after\n             dosing. In addition to using a condom, subjects must agree to practice an adequate\n             contraceptive method with female sexual partners to prevent pregnancy.\n\n        Exclusion Criteria:\n\n          -  Known or suspected hypersensitivity to ASP3652 or any components of the formulation\n             used.\n\n          -  Donation of blood or blood products within 3 months prior to admission to the\n             Clinical Unit.\n\n          -  Exposure to radiation for diagnostic reasons (except dental X-rays and plain X-rays\n             of thorax and bony skeleton (excluding spinal column)), during work or during\n             participation in a clinical study in the previous year."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02046798", 
            "org_study_id": "3652-CL-0003", 
            "secondary_id": "2011-004526-10"
        }, 
        "intervention": {
            "arm_group_label": "14C labeled ASP3652", 
            "description": "oral", 
            "intervention_name": "ASP3652", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Pharmacokinetics", 
            "ASP3652", 
            "14C radio-labeled", 
            "Phase 1"
        ], 
        "lastchanged_date": "January 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Leeds", 
                    "country": "United Kingdom", 
                    "zip": "LS2 9LH"
                }, 
                "name": "Covance Clinical Research Unit (CRU) Ltd."
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label Study to Evaluate the Pharmacokinetics of ASP3652 After a Single Oral Dose of 14C-labeled ASP3652 in Healthy Caucasian Male Subjects", 
        "overall_official": {
            "affiliation": "Astellas Pharma Europe B.V.", 
            "last_name": "Central Contact", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "area under the plasma concentration (AUC) - time curve from time zero to infinity (AUCinf), area under the plasma concentration - time curve from time zero to time of last measurable concentration (AUClast), maximum concentration (Cmax), time to attain Cmax (tmax), apparent terminal elimination half-life (t\u00bd)", 
                "measure": "Total radioactivity in plasma", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 6 and up to Day 9"
            }, 
            {
                "description": "area under the plasma concentration (AUC) - time curve from time zero to infinity (AUCinf), area under the plasma concentration - time curve from time zero to time of last measurable concentration (AUClast), maximum concentration (Cmax), time to attain Cmax (tmax), apparent terminal elimination half-life (t\u00bd)", 
                "measure": "Total radioactivity in whole blood", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 6 and up to Day 9"
            }, 
            {
                "description": "ratio concentrations per time point and AUC", 
                "measure": "Radioactivity ratio of plasma / blood", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 6 and up to Day 9"
            }, 
            {
                "description": "excretion rate and cumulative excretion", 
                "measure": "Radioactivity excretion in urine", 
                "safety_issue": "No", 
                "time_frame": "Urine: Days 1-6 and up to Day 25"
            }, 
            {
                "description": "excretion rate and cumulative excretion", 
                "measure": "Radioactivity excretion in feces", 
                "safety_issue": "No", 
                "time_frame": "Days 1-6 and up to Day 25"
            }, 
            {
                "description": "excretion rate and cumulative excretion", 
                "measure": "Radioactivity excretion in urine and feces", 
                "safety_issue": "No", 
                "time_frame": "Urine: Days 1-6 and up to Day 25"
            }, 
            {
                "description": "AUCinf, AUClast, Cmax, tmax, t1/2, apparent clearance after oral administration at steady state (CL/F), volume of terminal phase distribution at steady state (Vz/F)", 
                "measure": "ASP3652 in plasma", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 6 and up to Day 9"
            }, 
            {
                "description": "cumulative amount of unchanged drug excreted into the urine from time zero to infinity after single dose (Aeinf), cumulative amount of unchanged drug excreted into the urine from time zero to time of last measurable concentration (Aelast), renal clearance of the drug from plasma (CLR), percentage of unchanged drug excreted into the urine from time zero to infinity after single dose % of dose excreted (Aeinf%), percentage of unchanged drug excreted into the urine from time zero to time of last measurable concentration (Aelast%)", 
                "measure": "ASP3652 in urine", 
                "safety_issue": "No", 
                "time_frame": "Days 1-6 and up to Day 25"
            }, 
            {
                "description": "area under the plasma concentration (AUC) - time curve from time zero to infinity (AUCinf)", 
                "measure": "Ratio ASP3652 to 14C-radioactivity for AUCinf", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 6 and up to Day 9"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02046798"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Vital signs, 12-lead ECG, safety laboratory tests, physical examination, occurrence of Adverse Events (AE)", 
            "measure": "Safety and tolerability after a single dose", 
            "safety_issue": "No", 
            "time_frame": "Screening (Day  22 to Day  2) to End of Study Visit (7 to 14 days after (early) discharge)"
        }, 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Europe B.V.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}